A Food and Drug Administration (FDA) advisory committee on Thursday voted to recommend a new strain of flu in its vaccines for fall. This viral strain of flu is called subclade k.

The World Health Organization (WHO) also suggested that the variant is likely one reason flu vaccines were less effective this year. The Centers for Disease Control and Prevention in its Morbidity and Mortality Weekly Report (MMWR) noted that influenza vaccine effectiveness was 38 per cent to 41 per cent for preventing outpatient visits for children and adolescents and 41 per cent for preventing hospitalization.

For adults, the number was between 22 per cent to 34 per cent against influenza-associated outpatient visits and 30 per cent against influenza-associated hospitalization.

Although the figures were lower than those seen in recent flu seasons, the CDC emphasized that influenza vaccines still offer meaningful protection and continues to recommend vaccination. Last year alone, flu shots helped prevent around 5 million medical visits, 180,000 hospitalizations, and 12,000 deaths.

According to CDC estimates, influenza caused at least 26 million illnesses, 340,000 hospitalizations, and 21,000 deaths between October 1 and February 28.

At the committee meeting, Dr. Lisa Grohskopf, a medical officer in the CDC’s Influenza Division, noted that subclade K is currently the dominant flu variant circulating in the Northern Hemisphere.

However, the University of Minnesota’s Center for Infectious Disease Research and Policy highlighted that flu viruses mutate frequently. This means there is no certainty that the strains chosen now will be the ones circulating in the next flu season. Since vaccine production takes roughly six months, scientists must finalize the formulation as early as February or March.

Arnold Monto, an epidemiologist at the University of Michigan and acting chair of the Vaccines and Related Biological Products Advisory Committee, acknowledged the challenge, noting that selecting the right strains involves “a little bit of science and a little bit of luck,” according to Politico.

What Is Subclade K?

Known as the superfly, this is H3N2 'subclade K'. It is a type of seasonal influenza A virus and people have not encountered much of it in the recent years. This is why there is less immunity against it. However, the National Health Service (NHS), UK, has already sent out a 'flu jab SOS' to vulnerable people.

Daniel Elkeles, chief executive of NHS Providers, said that the major concern is that H3N2 is associated with a more severe illness and superflu could be "a very nasty strain of flu". He said that UK could be experiencing a "tidal wave" of illness.

The main strain circulating this winter is a drifted H3N2 variant, which the UKHSA says has left the community with “less natural immunity.” H3N2 strains tend to cause more serious illness in older adults than H1N1 strains and are linked to higher hospitalizations and deaths. This pattern adds further strain to the NHS during the winter months.

Antibiotics have long been considered lifesaving medicines, especially when it comes to treating serious bacterial infections. However, scientists have also known for years that these drugs can disturb the gut microbiome, the vast community of bacteria that live in our digestive system and play an important role in overall health. Now, new research suggests that the impact of some antibiotics on the gut may last far longer than previously believed.

A recent study has found that certain antibiotics may alter the gut microbiome in ways that persist for up to four to eight years after treatment. The findings were reported by scientists from Sweden and published in the journal Nature Medicine. According to the researchers, these long lasting changes may reduce the diversity of bacteria in the gut, which could potentially influence health over time.

Long term changes in gut bacteria

The gut microbiome contains hundreds of different species of bacteria that help regulate digestion, immunity, metabolism and even aspects of mental health. A healthy gut microbiome usually has a wide variety of bacterial species. When this diversity decreases, it may make the body more vulnerable to several health conditions.

Scientists have previously linked lower microbial diversity in the gut to problems such as obesity, diabetes and inflammatory bowel disease. Because antibiotics kill bacteria to fight infections, they may also eliminate beneficial microbes along with harmful ones. In some cases, this imbalance may take a long time to recover.

In the new study, researchers identified specific antibiotics that appeared to have the strongest and most lasting effects on gut bacteria. These included clindamycin, fluoroquinolones and flucloxacillin. The study’s lead investigator said that these medications were associated with significant changes in the overall composition of the gut microbiome.

Researchers observed that some bacterial species declined after antibiotic exposure while others increased. This shift altered the balance of the microbial community and was linked to reduced diversity.

Comparing antibiotic users and non users

To understand the relationship between antibiotics and gut bacteria, the research team analysed data from Sweden’s National Prescribed Drug Register. They then compared this information with gut microbiome samples from 14,979 adults living in Sweden.

The scientists examined the microbiome of people who had been prescribed different antibiotics and compared it with those who had not received any antibiotics during the same period.

Their analysis revealed that some antibiotics had stronger long term effects than others. For instance, penicillin V, one of the most commonly prescribed antibiotics for infections outside hospitals in Sweden, appeared to cause shorter lasting changes in gut bacteria.

However, other antibiotics were linked to more persistent shifts in the microbial ecosystem.

Effects that last for years

One of the most striking findings of the study was how long the effects could remain visible. According to the researchers, antibiotic use from four to eight years earlier was still associated with differences in a person’s gut microbiome.

Even a single course of certain antibiotics appeared to leave detectable traces years later. While the exact biological mechanisms are still not fully understood, the researchers believe antibiotics may permanently reshape parts of the microbial community in some individuals.

What this means for future antibiotic use

The researchers believe their findings could help guide future decisions about prescribing antibiotics. If two antibiotics are equally effective against an infection, doctors may eventually consider choosing the one that has a weaker impact on the gut microbiome.

Such insights could help balance the need to treat infections while also protecting long term gut health.

To better understand how the microbiome recovers over time, the scientists are now collecting a second set of gut samples from nearly half of the participants involved in the study. This follow up analysis may reveal how quickly the microbiome can recover after antibiotic exposure and which individuals may be more vulnerable to long lasting disruptions.

India has seen a significant rise in the cancer burden, with the cases rising to 1,569,793 in 2025, the government has informed the Parliament.

From more than 1.4 million in 2021, the cancer cases in the country rose to over 144,000 in the last five years, revealed Prataprao Jadhav, Union Minister of State for Health, in a written reply in the Rajya Sabha.

The increase in cases has been consistent:

• 1,426,447 cases in 2021
• 1,461,427 cases in 2022
• 1,496,972 cases in 2023
• 1,533,055 cases in 2024
• 1,569,793 cases in 2025

Similarly, cancer deaths also increased in the country -- 868,588 in 2025 from 789,202 in 2021.

The country reported about 15,000 cancer -related deaths each year:

• 789,202 deaths in 2021
• 808,558 deaths in 2022
• 828,252 deaths in 2023
• 848,266 deaths in 2024
• 868,588 deaths in 2025

Worst-Affected States And Key Reasons

Jadhav informed that bigger states with large populations have seen a major increase in cancer cases and deaths consistently in the last five years.

States with the highest estimated cancer cases in 2025 include:

Uttar Pradesh - 226,125

Bihar - 118,136 cases

West Bengal - 121,639 cases

Maharashtra - 130,465 cases

Rajasthan - 80,628 cases

States with the highest estimated cancer deaths in 2025 include:

Uttar Pradesh - 125,184 deaths

Bihar - 65,571 deaths

West Bengal - 67,093 deaths

Maharashtra - 71,696 deaths

Rajasthan - 44,402 deaths

Major reasons for the rise in cancer burden include:

• environmental factors such as industrial pollution, pesticide exposure,
• contaminated water sources, by pollutants like industrial waste, pesticides, heavy metals, and pharmaceuticals.

“The review provides a critical analysis of the current evidence, summarizing the association of water contamination, including industrial waste, pesticides, and heavy metals, with rectal and colorectal cancer,” Jadhav stated in the Upper House of the Parliament.

Cancer Care Facilities In India

Jadhav further informed that the government is tackling the growing burden by expanding cancer care infrastructure across the country.

The Ministry of Health and Family Welfare has implemented the Strengthening of Tertiary Care Cancer Facilities Scheme, which has approved:

• 19 State Cancer Institutes (SCI)
• 20 Tertiary Care Cancer Centers (TCCC)

Other high-quality comprehensive cancer care facilities in the country include:

• Tata Memorial Centre’s (TMC) six hospitals in Varanasi, Visakhapatnam, New Chandigarh, Guwahati, Sangrur, and Muzaffarpur
• Cancer treatment facilities in all 22 new AIIMS
• Advanced diagnostic and treatment facilities at the National Cancer Institute (NCI) at Jhajjar
• A second campus of Chittaranjan National Cancer Institute in Kolkata
• 297 Day Care Cancer Centers (DCCCs) as promised in the Union Budget 2025-26
• Free essential medicines and diagnostics at public health facilities
• Anti-cancer drugs in the Essential Drugs List at District and Sub-Divisional Hospitals
• Health insurance of Rs. 5 lakh per family annually for secondary and tertiary care under Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB PMJAY)
• Affordable Medicines and Reliable Implants for Treatment (AMRIT) Pharmacies providing access to affordable cancer medicines.

A new vaccine that targets the mosquito-borne dengue has proven to be over 80 percent effective in preventing the risk of severe disease for up to five years, according to a recent study conducted by Brazilian researchers.

The study, published in the journal Nature Medicine, confirmed that the tetravalent dengue vaccine -- Butantan-DV -- developed by the Butantan Institute in São Paulo, prevents hospitalizations and offers broader protection against all four dengue serotypes.

“This vaccine is establishing itself as a very important tool in the fight against dengue in Brazil, with the potential to contribute to reducing the circulation of the virus, in addition to individual protection,” said Fernanda Boulos, the institute’s medical director of clinical trials.

The Phase 3 Clinical Trial

The phase 3 clinical trial, conducted from February 2016 to July 2019, involved 16,235 participants between the ages of 2 and 59.

The researchers compared individuals who received a single dose of the vaccine (10,259) with those who were administered a placebo (5,976).

• The results showed
• 80.5 percent effectiveness against severe dengue cases
• no hospitalization in the vaccinated group vs 8 cases in the placebo group
• 65 percent effective in preventing symptomatic dengue

The Butantan-DV Vaccine

The Butantan-DV vaccine is tetravalent and offers protection against the four known serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.

The vaccine uses live viruses that have been “weakened” (attenuated) in a laboratory.

Once administered, the vaccine controls replication of these attenuated viruses in the body -- a process which induces the immune system to produce neutralizing antibodies specific to each of the four serotypes.

The vaccines create immunity specific to each serotype to enable the body to recognize and neutralize each variant individually.

The Butantan-DV vaccine was approved by the Brazilian Health Regulatory Agency (ANVISA) on November 26, 2025, for use by the Brazilian population aged 12 to 59.

The country's Ministry of Health has

• incorporated the vaccine into the national immunization program in January
• launched a pilot project to immunize 90 percent of the target population in states with high burden
• rolled out vaccination of primary care health professionals in February

Also read: Why Is Dengue Fever on the Rise Despite Vaccines?

Global Dengue Burden

Dengue is transmitted through infected mosquitoes, primarily the species Aedes aegypti.

Common Symptoms include:

• Sudden onset of high-grade fever.
• Intense headache
• Severe muscle, joint, or bone pain.
• Skin Rash that often appears 2–5 days after the fever starts
• Nausea and Vomiting
• Fatigue

According to the World Health Organization (WHO), about half of the world's population is now at risk of dengue.

It estimates that:

• about 390 million dengue infections occur annually worldwide
• nearly 100 million people develop symptoms each year

The two main authorized vaccines in the world against dengue are Dengvaxia and Qdenga.

These vaccines are designed to protect against all four serotypes of the virus, with a focus on reducing severe disease and hospitalizations.